[Comment] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer

Fred Saad and colleagues have published in The Lancet Oncology a trial on the combination of abiraterone acetate plus prednisone and olaparib in addition to conventional androgen depletion therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), who did not receive any first-line treatment.1